PRISM-PLUS: Demographics of Patients With Diabetes

Slides:

Advertisements

Similar presentations

Introduction The Question: Is HMO market share associated with adoption of cardiac-care technologies, and, in turn with treatments and outcomes for heart.

Advertisements

Collaborative on Reducing Readmissions in Florida May 2011.

K Fox, W Remme, C Daly, M Bertrand, R Ferrari, M Simoons On behalf of the EUROPA investigators. The diabetic sub study of.

Optimal Management of ACS Invasive vs Conservative Strategy

Cardiac Arrhythmias in Coronary Heart Disease SIGN 94.

Cardiovascular Disease in Women Module V: Prognosis and Treatment Outcomes.

New Treatment Advances in Acute Coronary Syndrome.

IMPACT OF DISPARITIES IN CARDIOVASCULAR CARE ON AFRICAN AMERICAN DEATHS Kevin Fiscella, MD, MPH University of Rochester School of Medicine & Dentistry.

VBWG HOPE-TOO: Results of the HOPE Study Extension.

High-Dose, Double-Bolus Eptifibatide (Integrilin™) in Non- Urgent Coronary Stent Intervention 6 Month Results of the ESPRIT Trial.

TACTICS- TIMI 18 Treat Angina with Aggrastat TM and Determine Cost of Therapy with an Invasive or Conservative Strategy.

Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial PEACE Trial Presented at The American Heart Association Scientific Sessions.

GUSTO IV ACS: Trial Design Abciximab versus placebo in very high-risk patients with non-ST elevation acute coronary syndromes: – ST  > 0.5 mm or – elevated.

Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.

Bivalirudin Monotherapy Improves 30-day Clinical Outcomes in Diabetics with Acute Coronary Syndrome: Report from the ACUITY Trial Frederick Feit, Steven.

1 Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial N Engl J Med 2001;344:

Transitions in Care-Heart Failure

Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Ungroup once.

Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals

MCV Campus Ginger Edwards.

Layth A. Mimish, M. Bakhshi, J. Buraiki,

For the HORIZONS-AMI Investigators

The IDEAL Study Reference

Impact of gender on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty L Grinfeld,

Scandinavian Simvastatin Survival Study (4S)

1224 STEMI pts, no reperfusion, < 24 hours from onset

EMPHASIS-HF Extended Follow-up

Online Gifts Buy for wishes happy mother's day to yours choice and with happy gifts find here:

End point Patients >75 y with renal insufficiency

Acute Heart Failure.

Cardiovacular Research Technologies

Jeff Macemon Waikato Cardiothoracic Unit

Group/causes of death Mortality (%) at 1 year Mortality (%) at 3 years

Two-Year Extended Follow-up in Patients Receiving a Zotarolimus-eluting Stent in the E-Five Registry Martin T. Rothman, Ian T. Meredith, Keyur Parikh,

Patient Presentation Patient’s Changing Condition Multiple Considerations To Balance.

Examining CV Effects of Basal Insulin Therapy

Heart Failure Prevention: Mission Impossible?

The Hypertension in the Very Elderly Trial (HYVET)

European Heart Association Journal 2007 April

MASTER Trial Inclusion Criteria

VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

CIBIS II: Cardiac Insufficiency Bisoprolol Study II

GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?

The HORIZONS-AMI Trial

2006 CRUSADE 2nd Quarter Results

For the HORIZONS-AMI Investigators

Preventive Angioplasty in Myocardial Infarction Trial

End point Fenoldopam, n (%) Dopamine, n (%) p

STENT THROMBISIS Insights on Outcomes and Impact of DUAL ANTIPLATELET THERAPY Permanent Discontinuation SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE.

RIDDLE-NSTEMI Trial design: Patients with NSTEMI were randomized to either immediate (within 2 hours) intervention or delayed (within 72 hours) intervention.

Erasmus MC, Thoraxcenter

Significance of Periprocedural Myocardial Infarctions in Percutaneous Coronary Interventions A New Look at an Old Topic Abhiram Prasad, MD, FRCP, FESC,

J Foland, J Fortenberry, B Warshaw,

Anaerobic threshold responder analysis

LRC-CPPT and MRFIT Content Points:

Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?

ARISE Trial Aggressive Reduction of Inflammation Stops Events

Infarct Size after Primary Angioplasty Patients With Bivalirudin

Update on the New Antiplatelet Agents:

Cause of death Treatment-arm events, % (n=45 054)

For the HORIZONS AMI Investigators

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Association of Troponin Elevation with Risk of Mortality in Acute Coronary Syndromes Mortality at 42 Days  % A study by Antman and.

Baseline Characteristics

ASCOT: randomised trial showing a decrease in cardiovascular mortality in patients treated with amlodipine/perindopril compared with atenolol/thiazide.

NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Presentation transcript:

PRISM-PLUS: Demographics of Patients With Diabetes Patients Without Patients With Diabetes Diabetes (n=1208) (n=362) Mean age (y) 62 66 Prior MI 40% 47% Heart failure 7% 16% PTCA 31% 28% CABG 23% 24% 1

PRISM-PLUS: MI/Death Outcomes in Patients With Diabetes 19.2% 5 15 10 20 15.5% P=0.004 11.2% % Patients 9.3% 4.7% 1.2% Day 7 Day 30 Day 180 2

PRISM-PLUS: MI in Patients With Diabetes 5 15 10 20 P=0.008 P=0.002 13.5% P<0.001 11.4% % Patients 7.8% 4.7% 1.8% 0% Day 7 Day 30 Day 180 3

PRISM-PLUS: Results in Patients With Diabetes Conclusion Tirofiban + heparin therapy resulted in a marked sustained reduction in major cardiac outcomes, particularly recurrent MI, in patients with diabetes presenting with UAP/NQWMI. 4